This week's Hudson Seminar will be held, Thursday 30th March 2017 at 12.00pm to 1.00pm in Seminar rooms 1 & 2, Level 2, TRF Building.
The speaker will be Professor Terrance Johns, Research Group Head, Oncogenic Signalling; Professor of Cancer Biology, Monash University and Director of the Brain Cancer Discovery Collaborative. He will be presenting "Novel therapeutic strategies for the treatment of high grade glioma."
After completing a PhD in melanoma in 1993 at Monash University, Prof Johns moved into multiple sclerosis research where he developed a new model of the disease that is still used today. In 1998, he commenced as a Research Fellow at the Ludwig Institute for Cancer Research and went on to establish the Oncogenic Signalling Laboratory, which has a focus on brain cancer. During this time he was a key leader in the development of mAb 806, a novel antibody that is directed to EGFR and currently is in Phase 3 clinical trial.
Since returning to Monash in 2008 he has continued to develop new therapeutic strategies for the treatment of brain cancer, including working with large pharmaceutical companies such as Amgen and Roche. In 2012, he founded the Brain Cancer Discovery Collaborative, an Australia-wide consortium of researchers and clinicians dedicated to ensuring that promising therapeutic discoveries are translated into the clinic for the treatment of patients with brain cancer.
Prof Johns has made major contributions in other research areas including ectopic pregnancy, where his novel therapeutic approach is about to enter final clinical trials.
A light lunch and refreshments will follow the presentation.